Adverum's Single Dose Wet AMD Gene Therapy Shows Robust Two Year Durability, Safety

• Adverum Biotechnologies Inc (NASDAQ: ADVM) announced new long-term data from the OPTIC trial of ADVM-022 gene therapy for neovascular or wet age-related macular degeneration (wet AMD).

• Data were shared at the Retina Society's Annual Scientific Meeting.

• The 2 x 10^11 vg/eye dose (n=15), planned to be evaluated in a future Phase 2 trial, showed an over 80% reduction in annualized anti-VEGF injection frequency in patients who previously required frequent injections.

• Over 50% of patients after a median follow-up of 1.7 years remained entirely free of any supplemental anti-VEGF injection.

• Retinal anatomy (mean Central subfield thickness versus baseline) to improved and vision (mean BCVA versus baseline) was maintained over time.

• All ADVM-022-related ocular adverse events were mild (81%) to moderate (19%) across all wet AMD patients.

• At the 2 x 10^11 vg/eye dose, ocular inflammation was minimal and responsive to steroid eye drops.

• The Company plans to present INFINITY trial data in diabetic macular edema at the American Society of Retina Specialists Annual Scientific Meeting.

• Related: Adverum Stock Falls As It Stops Testing Ocular Gene Therapy Candidate In Diabetic Macular Edema Patients.

• Price Action: ADVM stock is up 6.88% at $2.33 during the premarket session on the last check Monday.

See more from Benzinga

• Click here for options trades from Benzinga

• After Drug Distributors, Now Pharmacy Chains Face Trial In US Opioid Litigation: Reuters

• SEC Charges Former Goldman Sachs Officer For Insider Trading On 2 M&A Deals

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.